PolyPid, an Israeli biotech company, said it had agreed a $320 million deal with Azurity Pharmaceuticals to commercialize a drug aimed at preventing surgical site infections in the

PolyPid, an Israeli biotech company, said it had agreed a $320 million deal with Azurity Pharmaceuticals to commercialize a drug aimed at preventing surgical site infections in the US and Canada. Link Israeli PolyPid signs $320 million deal to sell drug preventing surgical infections in US, Canada D-PLEX100 is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent abdominal surgical site infections.